Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...

The childhood obesity epidemic in GCC countries has triggered a debate on the potential use of weight-loss medications such ...

David Ricks told a lunch audience at the Economic Club of Washington, D.C., that Zepbound could quickly become the most ...

Eli Lilly & Co. will begin studies to see if its blockbuster weight-loss medicines are also effective at controlling ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...

Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.

After a lucrative IPO in September, Richmond-based BioAge is seeing its biotech fortunes shift with its stock falling over 70 ...

Novo Nordisk's Lotte Bjerre Knudsen says her determination is a key part of the success, but she also stays humble.

They are currently approved for treating diabetes, obesity and those with a history of cardiovascular disease in people who ...